Torisel (temsirolimus) NDC 0008-1179

NDC codes

FDA NDC Directory

Product NDC (as listed)0008-1179Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00008-1179Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0008-1179-01	00008117901	1 KIT in 1 CARTON (0008-1179-01) * 25 mL in 1 VIAL, SINGLE-USE (0008-1279-01) * 1.8 mL in 1 VIAL, SINGLE-USE (0008-1125-01)Marketed from Jul 1, 2007

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Torisel
Generic name (nonproprietary): temsirolimus
Dosage form: Kit
Labeler: Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 022088
Marketing start: Jul 1, 2007
Listing expires: Dec 31, 2026
Identifiers: Product ID 0008-1179_8731b3b1-29d9-46b1-a443-822d8057f773SPL ID 8731b3b1-29d9-46b1-a443-822d8057f773SPL set ID 95b7dc92-2180-42f1-8699-3c28f609e674RxCUI 722289, 725108

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N400008117901 followed by a unit qualifier and the quantity

Package 00008-1179-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 26, 2025.

Indications (excerpt from the label)

TORISEL is indicated for the treatment of advanced renal cell carcinoma. TORISEL ® is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)